▶ Full Post Text
Look, I know there is an absolute flood of posts about Novo Nordisk on here lately, and we are all probably a bit burnt out on the endless Ozempic hype train. But hear me out, because most of the discussions I see barely scratch the surface. The article I’ve linked at the bottom actually goes deep into the mechanics of their businessmodel, their pricing headwinds, and the real risks they are facing, unlike the usual "weight-loss goes brrr" takes. To save you some time, I put together a quick summary below to highlight the core arguments being made. Although I did the research myself, I used a bit of AI to help condense my thoughts into a quick, readable format. Just keep in mind this is only a high-level overview; if you want to see the actual text, the math, the full financial numbers, and exactly how the valuation was calculated, all of that is laid out in detail on the Substack.
I have been looking closely at Novo Nordisk, and I feel like the broader market is fundamentally misunderstanding what this company actually is right now. Most people treat it as a pure weight-loss hype stock, riding the endless wave of Ozempic and Wegovy. But if you dig into their history and the mechanics of their businessmodel, it becomes clear that they are executing a massive transition into a cardiometabolic powerhouse focused on long-term organ protection. I wanted to share some thoughts on how they got here and why the current valuation might be mispricing the actual risks and rewards.
If we look at their origins, Novo isn’t some new biotech darling; they are a century-old Danish insulin machine that has always operated on a simple logic of turning complex science into industrialized, mass-produced patient access. Their real turning point wasn’t just stumbling upon a weight-loss miracle. It was a deliberate, decades-long shift away from classic pills toward complex biologics and peptides. By 2019, they clearly pivoted from just treating diabetes to aggressively targeting obesity and the nasty comorbidities that come with it, like cardiovascular and kidney disease. The absolute game-changer here was the SELECT trial in 2023. That study proved semaglutide actually reduces the risk of major cardiovascular events by twenty percent. That specific moment shifted their narrative completely from a lifestyle drug that people pay for out of pocket to a literal medical necessity. Suddenly, fighting for government and insurance reimbursement became a vastly different conversation. Of course, this explosive demand brought severe growing pains. They literally couldn’t make enough pens, leading to a massive eleven billion dollar acquisition of Catalent facilities just to fix their fill-finish bottlenecks. But now that the FDA considers the shortages largely resolved, Novo is losing its scarcity pricing power. Insurers are demanding steeper discounts, which is already putting a slight drag on their gross margins.
It ties directly to the hard reality of the business model. Making the drug is only half the battle. The real fight happens in commercialization: access and reimbursement, especially in the US, are negotiated outcomes. A small number of large players decide which drugs get “preferred” status, and Novo effectively buys that position with steep discounts. As a result, the list prices you see in headlines say little about what Novo actually earns net.
On top of that, two structural pressure points are coming into view: a Medicare price anchor that kicks in around 2027, and the patent cliff heading into 2031. That’s why the strategy is shifting toward two priorities: migrating patients to newer formats (like pills) and running the business more on scale and retention, not on maximizing profit per patient.
When you pull all of this together, you realize Novo Nordisk is serving an explosively growing market but facing exceptional frictions from insurers, governments, and incoming competition. If you build a valuation model that actually respects these headwinds, assuming net pricing gets squeezed and mass adoption is slowed down by reimbursement hurdles, you end up with a deliberately conservative fair value of roughly 343 DKK per share. The market seems to be aggressively pricing in these transition risks right now. There is obviously massive upside if access structurally opens up faster, but sticking to a conservative baseline keeps expectations realistic. I recently wrote a much more extensive deep dive into this entire transition and the specific math behind the valuation on our Substack, which you can read right [Here](https://thevaluationframework.substack.com/p/novo-nordisk-not-just-a-weight-loss)
I would love to hear what you guys think about their ability to maintain dominance once the pricing anchors really set in.